Amendment to Merger Agreement

Drugs Made In America Acquisition Corp. (the Company) and Power Analytics Global Corp (PAGC) entered into Amendment No. 1 to their merger agreement. The amendment changes the closing valuation under certain conditions. If the APQC Acquisition is not completed by November 1, 2026, the closing valuation for PAGC will be US$1,710,000,000 on a standalone basis. This standalone valuation excludes the APQC Acquisition and related intellectual property. The amendment also modifies the conditions for closing, including removing the requirement for APQC Acquisition completion by a specific date and the Company's right to terminate if it's not completed. Parties may later amend the agreement to include acquired assets like APQC, UltraSolar, or PolariQon intellectual property at their appraised value, subject to independent director approval and a supplemental fairness opinion, not exceeding the original US$2,850,000,000 ceiling. Joel A. Gallo has been engaged to provide a fairness opinion on the standalone valuation.